Med Life Sa · BVB:M
Med Life Sa — Q1 2021 Earnings Presentation
16 slides from Med Life Sa's earnings presentation, May 13, 2021
Slide 1: Q1 2021 Financial Results
Q1 2021 Financial Results Conference call presentation 13 May, 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Key messages 3m 2021 Highlights 3m 2021 • Outlook AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 3m 2021
Highlights 3m 2021 • Key messages 3m 2021 • Outlook 1 4/
Slide 5: Key messages 3m 2021
Key messages 3m 2021 ➢ MedLife Medical System recorded Pro-forma Sales of RON 370.6m RON in 3m 2021, increase by 40.3% compared to 3m 2020; ➢ IFRS Sales for 3m 2021 of 337.7m RON, increased by 27.9% compared to 3m 2020 (26.8% like to like); ➢ Strong operating performance, in line with the strategy o
Slide 6: Key messages 3m 2021 (Cont.)
Key messages 3m 2021 (Cont.) ➢ The surgeries also gained a large scale, the Romanians being aware that the postponement is not a solution for their problems and that they can come with confidence to MedLife units, not being exposed to high risks in terms of internal organization; ➢ Developed dedicat
Slide 7: Outlook
Outlook Main development segments include: 1. strengthening of the research department: the acceleration of the research initiatives initiated since the beginning of last year & maintaining the role of regional watchdog in monitoring the pandemic; 2. consolidation and expansion of the current hospit
Slide 8: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 8/
Slide 9: Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 9/ 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 10: Profit and Loss (1/3) explained
Consolidated Statement of Profit and Loss (1/3) explained 1) 3m 2021 Pro-forma vs. 3m 2020 IFRS ❑ Sales increased by 40.3%, to 370m RON ❑ OPEX increased by 29%, to 318m RON ❑ Threefold increase in EBIT, to 54.6m RON, leading to 14.7% margin (6.9% in the same period last year), due to improved financ
Slide 11: Profit and Loss (2/3): Operational KPIs
Consolidated Statement of Profit and Loss (2/3) Operational KPIs 11 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 12: Profit and Loss (3/3): OPEX Evolution
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution Release of 9 p.p. in margin due to: ➢ Increase in Consumable & repair materials with 3.4 p.p. of Sales due to reagents and materials related to PCR testing; ➢ Decrease in Commodities with 1.2 p.p. of Sales ➢ Decrease in Third party expen
Slide 13: Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) 13 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 14: Financial Position (2/2): Debt position
Consolidated Statement of Financial Position (2/2) Debt position 14 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 15: Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by good operating performance: 1. 49% increase in net cash from operating activities; 2. 217% increase in cash used in investing activities; 3. Cash used in financing activities of 8.2m RON 15 / 1.Highlights 2020 2. Financial
Slide 16: Q&A Session Thank you!
Q&A Session Thank you! 3 16 /